Crispr Therapeutics (NASDAQ:CRSP) Insider Buying and Selling Activity
Insider Ownership Percentage: 37.70%
Crispr Therapeutics (NASDAQ CRSP) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 3/4/2019 | Rodger Novak | President | Sell | 85,220 | $40.40 | $3,442,888.00 | 1,024,534 |  |
| 3/1/2019 | Rodger Novak | President | Sell | 8,693 | $40.01 | $347,806.93 | 1,024,534 | |
| 2/25/2019 | Rodger Novak | President | Sell | 14,780 | $40.00 | $591,200.00 | 1,033,227 | |
| 1/8/2019 | Rodger Novak | President | Sell | 17,310 | $35.09 | $607,407.90 | 1,130,697 | |
| 12/27/2018 | Vertex Pharmaceuticals (Europe | Major Shareholder | Buy | 40,198 | $24.93 | $1,002,136.14 | | |
| 12/24/2018 | Vertex Pharmaceuticals (Europe | Major Shareholder | Buy | 90,742 | $24.08 | $2,185,067.36 | | |
| 12/21/2018 | Vertex Pharmaceuticals (Europe | Major Shareholder | Buy | 22,742 | $22.58 | $513,514.36 | | |
| 12/18/2018 | Kurt Von Emster | Director | Sell | 72,934 | $29.85 | $2,177,079.90 | | |
| 7/5/2018 | Pablo J Cagnoni | Director | Sell | 7,500 | $62.00 | $465,000.00 | 5,816 | |
| 7/3/2018 | Pablo J Cagnoni | Director | Sell | 5,816 | $62.00 | $360,592.00 | 5,816 | |
| 6/5/2018 | Kurt Von Emster | Director | Sell | 920 | $12.51 | $11,509.20 | 90,000 | |
| 6/1/2018 | Samarth Kulkarni | CEO | Sell | 15,000 | $69.36 | $1,040,400.00 | 163,560 | |
| 5/17/2018 | Rodger Novak | President | Sell | 75,000 | $60.00 | $4,500,000.00 | 1,183,247 | |
| 5/14/2018 | Kurt Von Emster | Director | Sell | 650,000 | $54.39 | $35,353,500.00 | 5,629 | |
| 5/11/2018 | Kurt Von Emster | Director | Sell | 250,000 | $52.84 | $13,210,000.00 | | |
| 5/8/2018 | Bradley J Phd Bolzon | Director | Sell | 128,950 | $50.39 | $6,497,790.50 | 37,645 | |
| 4/30/2018 | Bradley J Phd Bolzon | Director | Sell | 30,566 | $50.29 | $1,537,164.14 | 43,986 | |
| 4/27/2018 | Thomas Woiwode | Director | Sell | 222,258 | $50.11 | $11,137,348.38 | | |
| 4/24/2018 | Versant Venture Capital V, L.P | Major Shareholder | Sell | 22,841 | $50.99 | $1,164,662.59 | | |
| 4/23/2018 | Bradley J Phd Bolzon | Director | Sell | 101,994 | $50.68 | $5,169,055.92 | 43,986 | |
| 1/16/2018 | Tyler Dylan-Hyde | Insider | Sell | 66,000 | $28.03 | $1,849,980.00 | 25,204 | |
| 1/5/2018 | Aktiengesellschaft Bayer | Major Shareholder | Buy | 527,472 | $22.75 | $11,999,988.00 | | |
| 1/5/2018 | Kurt Von Emster | Director | Sell | 92,337 | $26.96 | $2,489,405.52 | | |
| 1/2/2018 | Kurt Von Emster | Director | Sell | 37,754 | $26.76 | $1,010,297.04 | | |
| 1/2/2018 | Tyler Dylan-Hyde | Insider | Sell | 38,000 | $21.64 | $822,320.00 | 70,204 | |
| 12/29/2017 | Tyler Dylan-Hyde | Insider | Sell | 31,000 | $22.72 | $704,320.00 | | |
| 12/28/2017 | Tyler Dylan-Hyde | Insider | Sell | 700 | $21.75 | $15,225.00 | 115,904 | |
| 12/22/2017 | Thomas Woiwode | Director | Sell | 3,059 | $20.29 | $62,067.11 | 4,959 | |
| 12/22/2017 | Tyler Dylan-Hyde | Insider | Sell | 15,000 | $20.55 | $308,250.00 | 115,204 | |
| 12/15/2017 | Tyler Dylan-Hyde | Insider | Sell | 15,000 | $18.90 | $283,500.00 | 130,204 | |
| 12/4/2017 | Corp /De/ Celgene | Major Shareholder | Sell | 1,112,446 | $18.98 | $21,114,225.08 | | |
| 12/1/2017 | Corp /De/ Celgene | Major Shareholder | Sell | 87,991 | $19.10 | $1,680,628.10 | | |
| 11/29/2017 | Corp /De/ Celgene | Major Shareholder | Sell | 4,263 | $19.25 | $82,062.75 | | |
| 11/27/2017 | Corp /De/ Celgene | Major Shareholder | Sell | 27,990 | $19.75 | $552,802.50 | | |
| 11/27/2017 | Thomas Woiwode | Director | Sell | 200 | $20.24 | $4,048.00 | 8,218 | |
| 11/24/2017 | Corp /De/ Celgene | Major Shareholder | Sell | 26,010 | $20.00 | $520,200.00 | | |
| 11/24/2017 | Thomas Woiwode | Director | Sell | 1,700 | $20.21 | $34,357.00 | 8,218 | |
| 11/22/2017 | Corp /De/ Celgene | Major Shareholder | Sell | 256,000 | $19.76 | $5,058,560.00 | | |
| 11/20/2017 | Corp /De/ Celgene | Major Shareholder | Sell | 158,718 | $19.02 | $3,018,816.36 | | |
| 11/17/2017 | Corp /De/ Celgene | Major Shareholder | Sell | 51,282 | $18.44 | $945,640.08 | | |
| 11/15/2017 | Corp /De/ Celgene | Major Shareholder | Sell | 15,000 | $17.67 | $265,050.00 | | |
| 11/13/2017 | Corp /De/ Celgene | Major Shareholder | Sell | 65,093 | $17.76 | $1,156,051.68 | | |
| 11/10/2017 | Corp /De/ Celgene | Major Shareholder | Sell | 10,000 | $17.28 | $172,800.00 | | |
| 11/8/2017 | Corp /De/ Celgene | Major Shareholder | Sell | 16,875 | $18.06 | $304,762.50 | | |
| 11/6/2017 | Corp /De/ Celgene | Major Shareholder | Sell | 79,327 | $18.89 | $1,498,487.03 | | |
| 11/3/2017 | Corp /De/ Celgene | Major Shareholder | Sell | 22,759 | $19.10 | $434,696.90 | | |
| 9/5/2017 | Rodger Novak | CEO | Sell | 18,470 | $20.76 | $383,437.20 | 1,148,007 | |
| 8/30/2017 | Rodger Novak | CEO | Sell | 75,795 | $20.25 | $1,534,848.75 | 1,232,697 | |
| 8/30/2017 | Samarth Kulkarni | Insider | Sell | 27,154 | $20.08 | $545,252.32 | 110,893 | |
| 8/28/2017 | Kurt Von Emster | Director | Sell | 88,011 | $19.79 | $1,741,737.69 | | |
| 8/25/2017 | Kurt Von Emster | Director | Sell | 22,781 | $19.42 | $442,407.02 | | |
| 8/23/2017 | Kurt Von Emster | Director | Sell | 17,989 | $18.53 | $333,336.17 | | |
| 8/21/2017 | Kurt Von Emster | Director | Sell | 3,150 | $18.52 | $58,338.00 | | |
| 8/17/2017 | Kurt Von Emster | Director | Sell | 34,141 | $19.06 | $650,727.46 | | |
| 8/15/2017 | Kurt Von Emster | Director | Sell | 55,569 | $19.59 | $1,088,596.71 | | |
| 8/8/2017 | Kurt Von Emster | Director | Sell | 35,473 | $18.63 | $660,861.99 | | |
| 8/8/2017 | Tyler Dylan-Hyde | Insider | Sell | 15,000 | $18.57 | $278,550.00 | 167,727 | |
| 8/4/2017 | Kurt Von Emster | Director | Sell | 50,477 | $17.81 | $898,995.37 | | |
| 8/1/2017 | Kurt Von Emster | Director | Sell | 5,512 | $17.51 | $96,515.12 | | |
| 7/28/2017 | Kurt Von Emster | Director | Sell | 41,312 | $17.63 | $728,330.56 | | |
| 7/26/2017 | Kurt Von Emster | Director | Sell | 32,930 | $17.60 | $579,568.00 | | |
| 7/14/2017 | Kurt Von Emster | Director | Sell | 69,859 | $16.84 | $1,176,425.56 | | |
| 7/12/2017 | Kurt Von Emster | Director | Sell | 31,992 | $16.56 | $529,787.52 | | |
| 7/5/2017 | Kurt Von Emster | Director | Sell | 4,254 | $16.26 | $69,170.04 | | |
| 6/29/2017 | Kurt Von Emster | Director | Sell | 43,202 | $16.90 | $730,113.80 | | |
| 6/27/2017 | Kurt Von Emster | Director | Sell | 81,435 | $17.08 | $1,390,909.80 | | |
| 6/23/2017 | Kurt Von Emster | Director | Sell | 32,368 | $16.23 | $525,332.64 | | |
| 6/22/2017 | Rodger Novak | CEO | Sell | 10,825 | $15.37 | $166,380.25 | 1,225,830 | |
| 6/21/2017 | Rodger Novak | CEO | Sell | 30,222 | $15.01 | $453,632.22 | 1,230,397 | |
| 6/9/2017 | Rodger Novak | CEO | Sell | 5,303 | $15.02 | $79,651.06 | 1,219,208 | |
| 5/30/2017 | Rodger Novak | CEO | Sell | 3,650 | $15.02 | $54,823.00 | 1,218,655 | |
| 5/17/2017 | Rodger Novak | CEO | Sell | 50,000 | $16.26 | $813,000.00 | 1,239,082 | |
| 5/5/2017 | Rodger Novak | CEO | Sell | 616 | $16.92 | $10,422.72 | 1,215,621 | |
| 5/4/2017 | Rodger Novak | CEO | Sell | 49,384 | $16.30 | $804,959.20 | 1,230,929 | |
| 4/28/2017 | Tyler Dylan-Hyde | Insider | Sell | 21,639 | $16.78 | $363,102.42 | 180,495 | |
| 4/27/2017 | Samarth Kulkarni | Insider | Sell | 5,481 | $16.76 | $91,861.56 | 137,322 | |
| 4/25/2017 | Samarth Kulkarni | Insider | Sell | 11,615 | $16.78 | $194,899.70 | 137,047 | |
| 4/20/2017 | Rodger Novak | CEO | Sell | 50,000 | $17.88 | $894,000.00 | 1,262,711 | |
| 4/20/2017 | Tyler Dylan-Hyde | Insider | Sell | 10,177 | $17.71 | $180,234.67 | 200,274 | |
| 10/24/2016 | Corp /De/ Celgene | Major Shareholder | Buy | 800,150 | $14.00 | $11,202,100.00 | | |
| 10/24/2016 | Simeon George | Director | Buy | 66,500 | $14.00 | $931,000.00 | | |
(Data available from 1/1/2013 forward)
